RecruitingPhase 1NCT02811510
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study I
Sponsor
Yale University
Enrollment
40 participants
Start Date
Jun 1, 2016
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of the study is to characterize the acute effects of cannabinoids in women relative to men and to begin probing the mechanisms that may underlie gender differences.
Eligibility
Min Age: 18 YearsMax Age: 55 Years
Inclusion Criteria2
- At least one lifetime exposure to cannabis
- Good physical and mental health
Exclusion Criteria4
- Cannabis naive individuals
- Major current or recent stressors
- Taking estrogen supplements or oral contraceptive pills (for women)
- Sesame oil allergy
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGPlacebo
Placebo pill (no active cannabinoids)
DRUGDronabinol
10 mg capsule of Dronabinol will be administered orally.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02811510
Related Trials
Repeated CBD Administration and Cannabis Outcomes
NCT074348951 location
ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids
NCT0562970222 locations
Effects of Cannabidiol and Tetrahydrocannabinol on Microbiome and Neuroinflammation in HIV
NCT055148991 location
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study II
NCT047042711 location
Reducing Breathlessness With Dronabinol in COPD Patients
NCT064737011 location